バソプレシン拮抗薬市場(用途:中枢性糖尿病性消耗品、腎性糖尿病性消耗品、その他の用途)-世界の産業分析、サイズ、シェア、成長、トレンド、および予測、2023-2031年Vasopressin Antagonists Market (Application: Central Diabetes Insipidus, Nephrogenic Diabetes Insipidus, and Other Applications) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 バソプレシン拮抗薬市場 - レポートの範囲 TMRの調査レポート「バソプレシン拮抗薬の世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成... もっと見る
サマリーバソプレシン拮抗薬市場 - レポートの範囲TMRの調査レポート「バソプレシン拮抗薬の世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として考慮し、2017年から2031年までの世界のバソプレッシン拮抗薬市場の収益を提供します。また、2023年から2031年までの世界のバソプレシン拮抗薬市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、バソプレシン拮抗薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、および関連文書を参照しました。 また、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体なども二次調査の対象とした。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のバソプレシン拮抗薬市場のさまざまな属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界のバソプレシン拮抗薬市場における競争力学の変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界のバソプレシン拮抗薬市場への参入に関心のある企業にとっても貴重なツールになります。 本レポートは、世界のバソプレシン拮抗薬市場の競争環境について掘り下げています。世界のバソプレシン拮抗薬市場で活動する主要企業が特定され、これらの各企業は様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のバソプレシン拮抗薬市場のプレイヤーの属性です。 世界のバソプレシン拮抗薬市場レポートで回答された主要な質問 - 予測期間中に全地域でバソプレシン拮抗薬が生み出した売上/収益はどのくらいですか? - 世界のバソプレシン拮抗薬市場におけるビジネスチャンスは? - 市場における主な推進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大するのはどの地域市場か? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか? - 世界市場で事業展開している各社の市場ポジションは? バソプレシン拮抗薬市場 - 研究目的と研究アプローチ バソプレッシン拮抗薬の世界市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的へと続きます。本調査の目的、市場で活動する主要ベンダーや流通業者、製品承認のための規制シナリオについて詳しく解説しています。 読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。 本レポートでは、バソプレシン拮抗薬の世界市場を製品、エンドユーザー、地域の観点で分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界のバソプレシン拮抗薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Vasopressin Antagonists Market 4. Market Overview 4.1. Introduction 4.1.1. Drug Type Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031 5. Key Insights 5.1. Pipeline Analysis 5.2. Disease Incidence and Prevalence 5.3. Regulatory Approval 5.4. COVID-19 Impact Analysis 6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Drug Type, 2017–2031 6.3.1. Vaprisol 6.3.2. Tolvaptan 6.4. Market Attractiveness Analysis, by Drug Type 7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017–2031 7.3.1. Central Diabetes Insipidus 7.3.2. Nephrogenic Diabetes Insipidus 7.3.3. Other Applications 7.4. Market Attractiveness Analysis, by Application 8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Distribution Channel, 2017–2031 8.3.1. Retail Pharmacies 8.3.2. Hospital Pharmacies 8.3.3. Online Pharmacies 8.4. Market Attractiveness Analysis, by Distribution Channel 9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness Analysis, by Region 10. North America Vasopressin Antagonists Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Drug Type, 2017–2031 10.2.1. Vaprisol 10.2.2. Tolvaptan 10.3. Market Value Forecast, by Application, 2017–2031 10.3.1. Central Diabetes Insipidus 10.3.2. Nephrogenic Diabetes Insipidus 10.3.3. Other Applications 10.4. Market Value Forecast, by Distribution Channel, 2017–2031 10.4.1. Retail Pharmacies 10.4.2. Hospital Pharmacies 10.4.3. Online Pharmacies 10.5. Market Value Forecast, by Country, 2017–2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Drug Type 10.6.2. By Application 10.6.3. By Distribution Channel 10.6.4. By Country 11. Europe Vasopressin Antagonists Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Drug Type, 2017–2031 11.2.1. Vaprisol 11.2.2. Tolvaptan 11.3. Market Value Forecast, by Application, 2017–2031 11.3.1. Central Diabetes Insipidus 11.3.2. Nephrogenic Diabetes Insipidus 11.3.3. Other Applications 11.4. Market Value Forecast, by Distribution Channel, 2017–2031 11.4.1. Retail Pharmacies 11.4.2. Hospital Pharmacies 11.4.3. Online Pharmacies 11.5. Market Value Forecast, by Country/Sub-region, 2017–2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Drug Type 11.6.2. By Application 11.6.3. By Distribution Channel 11.6.4. By Country/Sub-region 12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Drug Type, 2017–2031 12.2.1. Vaprisol 12.2.2. Tolvaptan 12.3. Market Value Forecast, by Application, 2017–2031 12.3.1. Central Diabetes Insipidus 12.3.2. Nephrogenic Diabetes Insipidus 12.3.3. Other Applications 12.4. Market Value Forecast, by Distribution Channel, 2017–2031 12.4.1. Retail Pharmacies 12.4.2. Hospital Pharmacies 12.4.3. Online Pharmacies 12.5. Market Value Forecast, by Country/Sub-region, 2017–2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Drug Type 12.6.2. By Application 12.6.3. By Distribution Channel 12.6.4. By Country/Sub-region 13. Latin America Vasopressin Antagonists Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Drug Type, 2017–2031 13.2.1. Vaprisol 13.2.2. Tolvaptan 13.3. Market Value Forecast, by Application, 2017–2031 13.3.1. Central Diabetes Insipidus 13.3.2. Nephrogenic Diabetes Insipidus 13.3.3. Other Applications 13.4. Market Value Forecast, by Distribution Channel, 2017–2031 13.4.1. Retail Pharmacies 13.4.2. Hospital Pharmacies 13.4.3. Online Pharmacies 13.5. Market Value Forecast, by Country/Sub-region, 2017–2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Drug Type 13.6.2. By Application 13.6.3. By Distribution Channel 13.6.4. By Country/Sub-region 14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Drug Type, 2017–2031 14.2.1. Vaprisol 14.2.2. Tolvaptan 14.3. Market Value Forecast, by Application, 2017–2031 14.3.1. Central Diabetes Insipidus 14.3.2. Nephrogenic Diabetes Insipidus 14.3.3. Other Applications 14.4. Market Value Forecast, by Distribution Channel, 2017–2031 14.4.1. Retail Pharmacies 14.4.2. Hospital Pharmacies 14.4.3. Online Pharmacies 14.5. Market Value Forecast, by Country/Sub-region, 2017–2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Drug Type 14.6.2. By Application 14.6.3. By Distribution Channel 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (by tier and size of companies) 15.2. Market Share Analysis, by Company, 2022 15.3. Company Profiles 15.3.1. Otsuka 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Test Drug Type Portfolio 15.3.1.3. Financial Overview 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. Cumberland Pharmaceuticals 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Test Drug Type Portfolio 15.3.2.3. Financial Overview 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Mayo Clinic 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Test Drug Type Portfolio 15.3.3.3. Financial Overview 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Hopital du Sacre-Coeur de Montreal 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Test Drug Type Portfolio 15.3.4.3. Financial Overview 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 図表リストList of TablesTable 1: Global overview of Vasopressin Antagonists Table 2: Regional overview of Vasopressin Antagonists Table 3: North America Overview of Vasopressin Antagonists Table 4: APAC overview of Vasopressin Antagonists Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
SummaryVasopressin Antagonists Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Vasopressin Antagonists Market 4. Market Overview 4.1. Introduction 4.1.1. Drug Type Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031 5. Key Insights 5.1. Pipeline Analysis 5.2. Disease Incidence and Prevalence 5.3. Regulatory Approval 5.4. COVID-19 Impact Analysis 6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Drug Type, 2017–2031 6.3.1. Vaprisol 6.3.2. Tolvaptan 6.4. Market Attractiveness Analysis, by Drug Type 7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017–2031 7.3.1. Central Diabetes Insipidus 7.3.2. Nephrogenic Diabetes Insipidus 7.3.3. Other Applications 7.4. Market Attractiveness Analysis, by Application 8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Distribution Channel, 2017–2031 8.3.1. Retail Pharmacies 8.3.2. Hospital Pharmacies 8.3.3. Online Pharmacies 8.4. Market Attractiveness Analysis, by Distribution Channel 9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness Analysis, by Region 10. North America Vasopressin Antagonists Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Drug Type, 2017–2031 10.2.1. Vaprisol 10.2.2. Tolvaptan 10.3. Market Value Forecast, by Application, 2017–2031 10.3.1. Central Diabetes Insipidus 10.3.2. Nephrogenic Diabetes Insipidus 10.3.3. Other Applications 10.4. Market Value Forecast, by Distribution Channel, 2017–2031 10.4.1. Retail Pharmacies 10.4.2. Hospital Pharmacies 10.4.3. Online Pharmacies 10.5. Market Value Forecast, by Country, 2017–2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Drug Type 10.6.2. By Application 10.6.3. By Distribution Channel 10.6.4. By Country 11. Europe Vasopressin Antagonists Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Drug Type, 2017–2031 11.2.1. Vaprisol 11.2.2. Tolvaptan 11.3. Market Value Forecast, by Application, 2017–2031 11.3.1. Central Diabetes Insipidus 11.3.2. Nephrogenic Diabetes Insipidus 11.3.3. Other Applications 11.4. Market Value Forecast, by Distribution Channel, 2017–2031 11.4.1. Retail Pharmacies 11.4.2. Hospital Pharmacies 11.4.3. Online Pharmacies 11.5. Market Value Forecast, by Country/Sub-region, 2017–2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Drug Type 11.6.2. By Application 11.6.3. By Distribution Channel 11.6.4. By Country/Sub-region 12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Drug Type, 2017–2031 12.2.1. Vaprisol 12.2.2. Tolvaptan 12.3. Market Value Forecast, by Application, 2017–2031 12.3.1. Central Diabetes Insipidus 12.3.2. Nephrogenic Diabetes Insipidus 12.3.3. Other Applications 12.4. Market Value Forecast, by Distribution Channel, 2017–2031 12.4.1. Retail Pharmacies 12.4.2. Hospital Pharmacies 12.4.3. Online Pharmacies 12.5. Market Value Forecast, by Country/Sub-region, 2017–2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Drug Type 12.6.2. By Application 12.6.3. By Distribution Channel 12.6.4. By Country/Sub-region 13. Latin America Vasopressin Antagonists Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Drug Type, 2017–2031 13.2.1. Vaprisol 13.2.2. Tolvaptan 13.3. Market Value Forecast, by Application, 2017–2031 13.3.1. Central Diabetes Insipidus 13.3.2. Nephrogenic Diabetes Insipidus 13.3.3. Other Applications 13.4. Market Value Forecast, by Distribution Channel, 2017–2031 13.4.1. Retail Pharmacies 13.4.2. Hospital Pharmacies 13.4.3. Online Pharmacies 13.5. Market Value Forecast, by Country/Sub-region, 2017–2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Drug Type 13.6.2. By Application 13.6.3. By Distribution Channel 13.6.4. By Country/Sub-region 14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Drug Type, 2017–2031 14.2.1. Vaprisol 14.2.2. Tolvaptan 14.3. Market Value Forecast, by Application, 2017–2031 14.3.1. Central Diabetes Insipidus 14.3.2. Nephrogenic Diabetes Insipidus 14.3.3. Other Applications 14.4. Market Value Forecast, by Distribution Channel, 2017–2031 14.4.1. Retail Pharmacies 14.4.2. Hospital Pharmacies 14.4.3. Online Pharmacies 14.5. Market Value Forecast, by Country/Sub-region, 2017–2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Drug Type 14.6.2. By Application 14.6.3. By Distribution Channel 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (by tier and size of companies) 15.2. Market Share Analysis, by Company, 2022 15.3. Company Profiles 15.3.1. Otsuka 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Test Drug Type Portfolio 15.3.1.3. Financial Overview 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. Cumberland Pharmaceuticals 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Test Drug Type Portfolio 15.3.2.3. Financial Overview 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Mayo Clinic 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Test Drug Type Portfolio 15.3.3.3. Financial Overview 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Hopital du Sacre-Coeur de Montreal 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Test Drug Type Portfolio 15.3.4.3. Financial Overview 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview List of Tables/GraphsList of TablesTable 1: Global overview of Vasopressin Antagonists Table 2: Regional overview of Vasopressin Antagonists Table 3: North America Overview of Vasopressin Antagonists Table 4: APAC overview of Vasopressin Antagonists Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031 Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
Transparency Market Research社の製薬分野での最新刊レポート
本レポートと同じKEY WORD(industry analysis)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |